EVG - Strong Buy12 Feb 2020 15:21
There are a few catalysts that can really re-rate this stock:
- Non-dilutive funding
- Additional Investigator trials
- Monetise IP (they have a stable form of Sulforaphane)
Crazy valuation for a company with a working drug and £5m in cash.
Amati Global selling out has pulled the price down to these levels, I see a fantastic opportunity here